Tagged: J Lyle Bootman

Outcome Based Contracts and The Six Delta Platform

In recent months, there has been a pressing need in the United States for access to affordable medical services and pharmaceuticals. When J. Lyle Bootman first became Executive Director of the HOPE Center at the University of Arizona in 1986, it was with the mission to apply practical economic measures to the health care industry and management of health systems. Although J. Lyle Bootman retired as Executive Director in 2018, he has seen the HOPE Center’s mission realized in his former students’ published works.

One such former student, Dr. Nimer Alkhatib, has recently designed the groundbreaking platform, The Six Delta Platform for Outcome-Based Contracting for Pharmaceuticals. The Six Delta Platform is the first technical platform for outcome-based contracting and utilizes a “multidimensional price assessment in which the six dimensions are used to provide price variations.” Dr. Alkhatib and fellow researchers used the six dimensions to determine price assessment, varying from “Cost-effectiveness analysis and cost-utility analysis-based pricing” to “risk of efficacy failure-based pricing.” This work is vital to the future of outcome-based contracts as few metrics have been created to identify an accurate base price for contracts.

Outcome-based contracts are largely considered the pharmaceutical industry’s response to the public’s concerns over rising drug prices and their calls for regulations. These contracts are based on the agreement that a drug’s price will match the value of its effectiveness. If a drug does not perform to specific standards, a refund is offered once the treatment is completed. One of the most well-known examples of outcome-based contracts was Harvard Pilgrim’s 2017 agreement with Spark Therapeutics. The outcome-based contract covered Spark Therapeutics’ retinal dystrophy gene therapy treatment, Luxturna, which costs over $850,000 for a single treatment. The agreement stated that if Luxturna should fail to treat the anonymous patient’s retinal dystrophy, that Harvard Pilgrim would receive a rebate from Spark Therapeutics.

Today, outcome-based contracts are still being tested as a viable tactic to reduce pharmaceutical spending and lower generic drug prices. While outcome-based contracts are becoming more common within the US, they are still regarded with uncertainty from a lack of research and data. Jesse Bootman stresses that contracts are still relatively new and possess the potential to redefine the pharmaceutical industry, which is why Dr. Alkhatib and his fellow researchers’ platform The Six Delta Platform is essential to the future of this new pricing model.

Extensive Research Work Gives J Lyle Bootman Pause over New COVID-19 Treatment

Jesse Lyle Bootman

The local pharmacy is the typical point of contact for those who need access to drugs and medication. This well-regulated institution exists to give the general public access to the health-promoting products they need while still putting medical experts in charge. A coronavirus vaccine, which remains in development in the U.S., will undoubtedly find its way into thousands of pharmacies across the country. The near-term future of vaccine development, public roll-out and how its eventually administered is of great interest to J Lyle Bootman. That’s because he spent decades in the pharmacy, medicine and public health sector. His current role at a data-oriented global health firm also translates to the grand scale of distribution as it pertains to future coronavirus vaccines.

According to an Aug. 23, 2020 article from USA Today, the announcement of “a potential COVID-19 vaccine” could mean “infusions of antibody-rich plasma from recovered patients” that can “aid the immune systems of the sick.” Additional news reports reveal that 70,000 people have already been given the convalescent plasma and this form of treatment has been under investigation since March. Adding further complication is that the supply is currently limited so despite the welcome good news, it’s not yet the “cure” we’ve been waiting for since early 2020. Mr. Bootman’s previous role as co-chair of The Institute of Medicine, which published “Preventing Medication Errors” during his tenure, shows his commitment to smart and effective medicine administered by professionals at a pharmacy. While the effectiveness of this new plasma method is far from proven, it comes at a critical time. More than 5.7 million Americans have tested positive for the coronavirus and 176,000 citizens have died because of it.

Because of Jesse Lyle Bootman’s own lengthy career in this sector, and hundreds of personal research projects to his name, he’s a staunch supporter of doing your homework. His work into drug-related problems among elderly patients has renewed relevance here, as COVID-19 infections have largely proved deadly to those in their 70s and up. J Lyle Bootman’s work as co-investigator and principal investigator on this topic was conducted on behalf of The University of Arizona. The school is also where he was a faculty member of 40 years, including time as dean of the college of pharmacy. Even his current role, where Mr. Bootman helps to reduce medication-related problems, is relevant to possible coronavirus treatment plans. The goal of every medical professional is to spot any safety, efficacy and cost concerns before patients even enter the picture.

Pandemic Places Crucial Role of Local Pharmacists in Clear View, says Jesse Lyle Bootman

Jesse Lyle Bootman wearing white coat in pharmacy lab

Your local pharmacist is a crucial resource who provides access to modern medicine. The coronavirus pandemic has caused a spike in demand for access to medicine and medical-related data. This has put those in the medical field in a precarious spot, as every move they make could have serious consequences. The seriousness of this career is one of the many lessons Jesse Lyle Bootman sought to instill in students as a former professor of pharmacy, medicine and public health at the University of Arizona. It’s for these reasons that J. Lyle Bootman read with much interest a recent DrugTopics.com article on state-sanctioned COVID-19 tests administered by pharmacists. This is a truly a life-or-death matter and the bar has been set high.

According to the article, “authorized licensed pharmacists” got the green light this spring to use tests that had been approved by U.S. Food and Drug Administration. Not every state was prepared to follow through on this process, however. “In California, pharmacy, medical, and consumer groups lobbied Gov. Gavin Newsom and regulators for nearly six weeks before the state’s Department of Consumer Affairs eased restrictions that prevented most pharmacies from testing,” the article notes. New York’s governor had to issue his own executive order that cleared the path for pharmacists to administer these tests. Additional hurdles include funding, reimbursement and insurance policies.

An additional recent article from DrugTopics.com also notes that some tests for COVID-19 were producing too many “false negatives.” At the root of the problem were patients with low virus levels “during the earliest stages of an infection,” which meant their negative test results were simply incorrect. As an accomplished researcher, J. Lyle Bootman knows that it takes time to spot gaps in the process and outright errors. Fortunately, the results of this Johns Hopkins study include the call for improved tests that will “diagnose patients accurately and quickly, which will allow for better control of the virus’s spread.”

Having spent nearly three decades as the dean of The University of Arizona College of Pharmacy, J. Lyle Bootman is no stranger to the complicated workings of this field of medicine. His current role as the senior vice president of a data-driven healthcare firm has only deepened his resolve to help all patients. The coronavirus pandemic has exposed so many shortcomings in our society; J. Lyle Bootman is committed to keeping pharmaceutical access off that list.

J. Lyle Bootman’s Data-Driven Healthcare Career tells him Doctor Shortage can be Solved

Jesse Lyle Bootman

From income inequality to means of mass production, the coronavirus has taught the entire planet lessons about issues unrelated to health. Of course, the COVID-19 flu pandemic has also shed light on long-simmering topics within the health community and a supposed “doctor shortage” is among them. As a former professor of pharmacy, medicine and public health at the University of Arizona, J. Lyle Bootman was responsible for overseeing the education of medical experts in training. His vision and direction were also put to use while assisting the Arizona Health Sciences Center as a senior vice president for health services. In this role, Mr. Bootman helped guide four health professions colleges during a transition period. Since he is already well-versed in academia and its issues – and since no doctor lands that job without extensive schooling – Jesse Lyle Bootman is closely following recent headlines related to a “doctor shortage.” 

According to an April 2020 article from the magazine Washingtonian, the number of doctors entering employment in the U.S. is directly tied to payments from the Centers for Medicare & Medicaid Services to hospitals. Those funds are used to hire “resident” doctors and this is a “crucial bridge” crossed before becoming a licensed physician. In short, the funding to increase the total number of doctors isn’t there and as such, “the federal government has enormous leverage over the number of new physicians that enter medicine each year.” By no means is this a nefarious way of controlling the medical field in the U.S., says J. Lyle Bootman, but it is something that has been made worse by the coronavirus. Currently,  Mr. Bootman is the senior vice president for global health and consumer initiatives for a New Jersey-based healthcare company. Wrangling data to help make informed decisions is what he has spent decades doing and to help stem a shortage in doctors is going to require educated anticipation. 

A recent Consumer Affairs article points out that 18 percent of doctors who responded to a recent U.S. survey plan to retire in the near term. This would place increased strain on a shortage – but there are silver linings to be seen, says J. Lyle Bootman. “The coronavirus has led to a huge increase in the number of physicians who are using telemedicine to treat patients remotely,” the article states, and that’s innovation in action. Mr. Bootman has authored hundreds of research articles and looked at big issues at a very granular level. As one of the 50 most influential pharmacists in the U.S., according to American Druggist, J. Lyle Bootman has shown that studying the issues we are faced with and then rolling out plans to solve them is the logical path forward. COVID-19 has tested so many societal structures but data, when used correctly, can steer us toward better days.